Atai Life Sciences Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.28 profit in 3Q 2023)

Atai Life Sciences (NASDAQ:ATAI) Third Quarter 2024 Results

Key Financial Results

• Net loss: US$26.3m (down by 159% from US$44.2m profit in 3Q 2023).
• US$0.16 loss per share (down from US$0.28 profit in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Atai Life Sciences Earnings Insights

Looking ahead, revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 1.5% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for Atai Life Sciences (2 don't sit too well with us!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.